The company has massive low-carbon methanol projects in the works in Chile, Uruguay, Brazil, the US, and Tasmania. The cost ...

By selling its China business to AstraZeneca, FibroGen can focus on developing a prostate cancer drug and potentially ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences (RCUS) presented new data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Bhubaneswar: Chile-based e-fuel company HIF Global has expressed interest to invest around $1 billion in Odisha’s renewable ...

当代人生活压力大，“头”等大事频频告急！走在街头，能看到不少人年纪轻轻就被脱发问题困扰，发际线不断后移，发缝越来越宽。每次洗头、梳头，大把头发脱落，让人焦虑不已。

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...